Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?

Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?

Source: 
Fierce Pharma
snippet: 

Teva's Ajovy has been battling against intense competition in the CGRP migraine prevention field at a disadvantage: It's delivered by syringe, and its rivals use simpler, less intimidating autoinjectors. Until now. But can its own device approval drive a 25% market share grab as execs hope?